The Lawrence Transplant Foundation
1629 K Street, N.W.
Washington, DC 20006
DANIEL F. GILLIS
Mr. Gillis has an extensive and successful background as a senior executive. Most recently, Mr. Gillis was CEO of SAGA Systems (“SAGA”), a NYSE traded enterprise software company with over $200 million of revenue and 900 employees. As CEO of SAGA, Mr. Gillis led a management buyout of the company from its German parent for $85million in April of 1997. After closing the acquisition, Mr. Gillis completed two acquisitions, led an IPO on the NYSE in November of 1997, and dramatically grew operating profit, from $10 million to $45 million over three years. SAGA was ultimately reacquired by the German seller for over $300 million, generating over 10 times the capital invested by the buyout sponsor, Thayer Capital. Prior to SAGA, Mr. Gillis was Executive Vice President of Falcon Systems, a $180 million Maryland based interactive equipment company serving the Federal market. Mr. Gillis guided the company through an unprecedented growth period, taking them from $13 million in revenue to $180 million that led to their 1994 acquisition by GTSI, a NASDAQ company. Mr. Gillis was a member of the NYSE Listed Companies Advisory Board. In addition, Mr. Gillis served as a member of the Board of Iconixx, an internet services firm based in Houston, Texas and Vigilinx, a digital Security Company based in New Jersey. He was also on the Board of Directors of Cysive, a web Software Company based in Reston, Virginia that was recently sold in a management buyout. He is currently a Director of SciQuest, a web based Software Company that was acquired by Trinity Ventures of California in 2004. In 1999, Mr. Gillis was selected as the Ernst & Young Entrepreneur of the Year. Mr. Gillis is a graduate of the University of Rhode Island and is married with three children. “I met Jim Lawrence in 1990 through a business relationship and we have been friends ever since. Jim is a role model for people struggling with the effects of a transplant and I believe this Foundation will help many transplant candidates dramatically improve their outlook.”
Board of Directors